Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;135(1):48-78.
doi: 10.1016/j.bja.2025.04.001. Epub 2025 May 16.

Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement

Affiliations

Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement

Adriana D Oprea et al. Br J Anaesth. 2025 Jul.

Abstract

The perioperative management of patients using glucagon-like peptide 1 receptor agonists remains a topic of debate. While several multisociety statements have been published recently, the recommendations vary significantly in terms of medication management and preoperative fasting protocols for these patients. This document represents a multidisciplinary consensus statement led by the Society for Perioperative Assessment and Quality Improvement (SPAQI). It provides updated recommendations based on a modified Delphi process and supported by a systematic review of the current literature. The recommendations address management of the glucagon-like peptide 1 receptor agonists perioperatively, and preoperative fasting times for both solids and liquids. SYSTEMATIC REVIEW PROTOCOL: PROSPERO (CRD42023438624).

Keywords: diabetes mellitus; gastric emptying; glucagon-like peptide 1 receptor agonists; major adverse cardiovascular events; obesity; perioperative care.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest GEU receives grant support from Novo Nordisk, Merck, Insulcloud, Dexcom, Abbott, AstraZeneca, and Bayer. BJS receives funding from UpToDate, IARS, and Medtronic, DLH receives funding from Pharmacosmos and UpToDate. HA receives research funding from Phenomix Sciences and the USA National Institute of Health (K12AR084222). She also participates in advisory boards for Novo Nordisk. All other authors declare that they have no conflicts of interest.

Publication types

Substances